Cross-linking of Fas By Antibodies to a Peculiar Domain of gp120 V3 Loop Can Enhance T Cell Apoptosis in HIV-1-infected Patients

By Franco Silvestris,* Shigekazu Nagata,‡ Paola Cafforio,* Nicola Silvestris,* and Franco Dammacco*

From the *Department of Biomedical Sciences and Human Oncology, University of Bari, Section of Internal Medicine, 70124 Bari, Italy; and ‡Department of Molecular Biology, Osaka Bioscience Institute, Osaka 565, Japan

Summary
Previous studies have demonstrated that T cell–reactive antibodies in HIV-1 infection contribute to lymphocyte depletion by cytotoxicity that involves differential membrane targets, such as the 43.5-kD receptor on CEM cells. Here, we show that these antibodies bind Fas as result of a molecular mimicry of the gp120. Both flow cytometry and immunoblotting using the human Fas–transfected mouse WC8 lymphoma revealed positive binding of immunoglobulin G from several patients to a 43.8-kD membrane receptor that also reacts with the CH11 anti-Fas monoclonal antibody. Specificity to Fas was further confirmed to chimeric recombinant human Fas-Fc by ELISA, whereas overlapping peptide mapping of a Fas domain (VEINCTR–N) shared by gp120 V3 loop demonstrated a predominant affinity to the full-length 10-mer peptide. Four anti-Fas affinity preparations greatly increased the subdiploid DNA peak of CEM cells similar to agonist ligands of Fas. In addition, anti-Fas immunoglobulin G strongly inhibited the [3H]thymidine uptake of CEM cells in proliferative assays, inducing a suppression as high as provoked by both CH11 mAb and recombinant human Fas ligand. Since anti-Fas were reactive to gp120, it is conceivable that antibodies binding that domain within the V3 region are effective cross-linkers of Fas and increase apoptosis in peripheral T cells. These results suggest that autologous stimulation of the Fas pathway, rather than of lymphocytotoxic antibodies, may aggravate lymphopenia in a number of HIV-1+ subjects.

Activation-induced apoptosis of antigen-primed CD4+ and CD8+ T lymphocytes has been well documented in peripheral cell cultures from HIV-1+ patients, and has been postulated as a mechanism that is primarily involved in the immunopathogenesis of AIDS (1–4). Chronic immune activation of those cells is indeed thought to significantly enhance their susceptibility to apoptosis (5–7), whereas the subsequent antigenic stimuli may drive the death program to completion (8, 9).

Apoptosis is a signal-dependent suicidal process that is regulated in part by Fas or Apo1/CD95 (10–13), namely a 45-kD membrane receptor that transduces the death signal to its intracellular pathway after ligation with a natural ligand (Fas–L)1 active in trimeric form (14). Fas-mediated apoptosis makes a physiological contribution within the immune system in suppression of autoreactive T cell clones in the thymus (15), as well as in the regulation of its normal response (16) and cytotoxicity (17). Moreover, the mutated expression of genes encoding either Fas or Fas–L may afford resistance to apoptosis in mature T cells from lpr (18) or gld (19) mice, respectively. Both phenotype strains suffer from a lymphoproliferative disorder that leads to autoimmune syndromes (20) that are highly similar to SLE. In this disorder, the abnormal expression of soluble Fas (21) is associated with an increased rate of apoptosis in peripheral lymphocytes (22), suggesting the involvement of Fas deregulation in driving the SLE autoreactivity. Further evidence of the role of apoptosis in human autoimmunity has been provided by the demonstration that synovial cells from patients with rheumatoid arthritis are highly subject to death by Fas overexpression (23).

Autoimmunity (24–26) and Fas overexpression (27, 28) have also been described during the HIV-1 infection, even though no linkage between these conditions has been documented so far. We have recently reported that the abnormal overexpression of Fas by T cells in advanced HIV-1 infection correlates with the high responsiveness of the receptor

---

1Abbreviations used in this paper: aa, amino acid; CDC, Center for Disease Control and Prevention; PI, propidium iodide; RF, rheumatoid factor; rFas–L, recombinant human Fas ligand.
to its extracellular binding, even when using a monomeric ligand, as provided by mouse IgG1 mAb from the UB-2 clone (29). This finding emphasizes the hypothesis that Fas is somehow involved in the increased in vitro apoptosis of peripheral cells from HIV-1–infected individuals, and that the Fas pathway may play a pathogenic role by aggravating the T cell lymphopenia that is related to the progression of their disease. Aggravation has also been associated to autoimmune phenomena (30–32), and we have illustrated the lymphopenic effect of T cell–reactive autoantibodies in a considerable number of patients, since their serum levels apparently parallel the progression of CD4+ lymphocyte decline (33, 34). As a result of their ability to react with a 43.5-kD marker located on CD4+ clonotypic lymphoblasts of the CEM line, these molecules were found to be powerful inducers of cytolyis in complement-mediated cytotoxicity, when either peripheral T lymphocytes or CEM were used as the cell target (35).

In the present study, we provide evidence that in most patients with variable serum titers of T cell binding antibodies, the molecular target of these reactivities may include Fas. Therefore, activation of the Fas pathway by autoantibodies is at least partly responsible for the increased apoptosis that contributes to T cell depletion because of the receptor’s high sensitivity. Since antibodies to Fas are also reactive to a specific epitope shared by the gp120 V3 loop of HIV-1, however, it is conceivable that antibodies primarily elicited to neutralize the virus may cross-react with Fas and activate its function through molecular mimicry. The increment of apoptosis by autologous Fas stimulation rather than lymphocytotoxic antibodies may therefore account for the aggravation of lymphopenia in patients whose HIV-1–neutralizing IgG may include specificity to the viral domain shared by Fas.

Materials and Methods

Study Subjects. Peripheral blood samples were obtained from 74 HIV-1+ individuals at different Center for Disease Control and Prevention (CDC) stages (36) who were hospitalized at the Department of Internal Medicine and Oncology of the University of Bari. The study group included 55 former intravenous drug users, 10 heterosexual women with no history of intravenous drug use, 7 heterosexual women with no history of intravenous drug use, and 2 hemophilic men. 67 uninfected donors provided control blood samples. All subjects gave their informed consent, and the study was approved by the ethical committee of the University of Bari. In most instances, sera were aliquoted and stored at −80°C until use.

Detection of T cell–reactive Antibodies. Sera were screened for the presence of antibodies to T cell membrane by an optimized ELISA, using the CEM plasma membrane extract as antigen (34). Briefly, the 96 flat-well microtiter plates were coated overnight with 10 µg/ml of lysed membrane and were further incubated for 3 h with sera diluted 1/200. The plates were then supplemented with a goat peroxidase–conjugated anti–human IgG and in parallel with anti-IgM antiserum, and were subsequently read in a micro-ELISA reader (Titertek, Flow Laboratories, Irvine, Scotland) after their OPD (O-phenylenediamine) color development. Each sample was tested in triplicate, and each test included the control group. Patients’ sera with absorbance higher than the mean + 3 SD of control values in each isotype test were considered positive for antibody detection.

Anti-Fas Specificity of T Cell–reactive Antibodies. A number of different approaches were adopted to investigate the affinity of CEM-reactive IgG and IgM to Fas. First, we used indirect immunofluorescence analysis with the murine WC8 lymphoma cell line transfected with human Fas as substrate, and its Fas-negative mutant WR19L as a control (37). Preliminary experiments included the preparation of cytocentrifuged cell suspensions from both cell lines, followed by incubation with sera and subsequent treatment with the FITC-conjugated rabbit anti–human IgG and IgM. The slides were then evaluated under a UV microscope. Furthermore, the sera were tested in a flow cytometry assay, using a FACScan® (Becton Dickinson & Co., Mountain View, CA). 3 × 10^6 cells from each line were separately incubated with 50 µl of serum diluted 1/80, and then washed and further treated with the FITC-conjugated antiserum to each class of antibody. Control cell preparations were incubated with anti-T negative sera derived from both patients and controls, whereas an additional check included the treatment of cell suspensions with polyspecific human IgG from commercial preparations, as well as the incubation of cell preparations with only the labeled antisera.

The second approach included immunoblotting analysis, using the membrane lysate from both WC8 and WR19L cell lines as a substrate. Purified plasma membrane extract was obtained by nonionic detergent lysis followed by sequential centrifugations at 400 and 100,000g for clearance of nuclei, as well as the removal of the cytoskeletal component and insolubilized membrane, respectively. The membranes were then run in PAGE and further electroblotted to nitrocellulose. Strips cut from the nitrocellulose sheet were incubated with serum samples diluted 1/50, and were then washed and treated with alkaline phosphatase–labeled anti–human IgG and IgM until the nitro blue tetrazolium chromogenic staining completed the test. The molecular weights of the bands detected by the enzyme-labeled antiserum were evaluated by a standard migration curve obtained in each test by rainbow–colored markers (Amer sham International, Bucks, UK).

An evaluation was also made of the specificity detected in both flow cytometry and immunoblotting by an additional ELISA, using the recombinant human Fas (rFas) as antigen. This substrate is a chimeric protein product, since it is conjugated to the Fc portion of human IgG to optimize the biological stability (12). The ELISA was then installed by coating the plates with 10 µg/ml of antigen and subsequent incubation of sera diluted 1/100 for 5 h. Equivalent concentrations of mouse mAb anti–human κ and λ light chains (Immunotech, Marseille, France) were added to the wells, and the test was completed using a goat peroxidase–conjugated anti–mouse IgG. Parallel control ELISA plates coated with Fc fragment alone were prepared with the same mAbs and labeled antiserum to calculate the basic reactivity to Fc potentially present in anti-rFas specificities. The anti–Fc ELISA, including the measurement of IgM rheumatoid factor (RF) levels, was performed concurrently to the anti–rFas assay, whose values were referred to as the relative anti-Fc reactivities. Four RF-positive sera from HIV-1–uninfected patients were also tested as controls.

Evaluation of Specificity to Sequential Peptides of Fas. Sera with positive anti-Fas–reactivity values were also investigated to define their molecular specificity to peculiar epitopes of the Fas molecule by peptides produced by an automated synthesizer (Biocrom Biolyxin 4170; LKB, Sweden) by Fmoc chemistry, according to the manufacturer’s protocols. Thus, we installed a new

2288 Anti-Fas Antibodies in HIV-1+ Patients
ELISA using as substrate 10-mer overlapping peptides resembling the linear sequence of Fas between 90 and 117 amino acid (aa) positions. Conformity of peptide binding to plates was assessed by parallel tests using KLH as a carrier protein (38) with respect to uncoupled peptides. Since all 10-mer peptides appeared to bind the ELISA solid phase equally efficiently as in their glutaraldehyde–KLH–coupled form, the plates were coated with uncoupled antigen to prevent any cross-reactivity with KLH (39). Peptides included the 8-aa stretch (VEINCTR–N; position: 99–108 of Fas) structurally shared by the third N-glycosylation site of the gp120 V3 loop (40). This sequence is invariably expressed by the HIV-1m strain during both primary infection and advanced disease (41), whereas a single substitution of Glu (E) by Gln (Q) occurs within the domain in the V3 loop from other virus subgroups, including HIV-1MN and HIV-1RF (42). Therefore, we used the 17 overlapping peptides of VEINCTR–N to test its progressive aa antigenicity, whereas the VEINCTRPN (IIIB strain) and VQINCTRPN (MN strain) single peptides were also coated in parallel plates. This control was addressed to evaluate a potential prevalence in specific HIV-1 strain infection. After incubation, the plates were supplemented with sera, and the assay was completed as a standard ELISA.

Isolation of Anti-Fas Antibodies. Sequential affinity chromatography was used to purify antibodies to Fas from sera 3, 41, 54, and 59, which displayed the highest reactivity to the antigen in the previous ELISAs. Purified anti-Fas preparations were obtained by recycling absorption of 7–12 ml of serum on Sepharose 4B columns coupled with the WC8 membrane lysate. The absorbed material was then eluted by glycine-HCl acidic buffer (pH 2.8) and promptly adjusted to neutrality by the addition of Tris base (pH 8.3). Next, the eluates were repeatedly passed through WR19L lysate affinity columns to absorb possible unrelated specificities on the Fas-negative parental cell line. In two instances (sera 54 and 59), we optimized these purification experiments by absorption on VEINCTR-coupled Sepharose columns. The protein content of eluted fractions was assessed by SDS-PAGE, whereas aliquots of these affinity-isolated anti-Fas antibodies were dialyzed against PBS and sterilized by filtration for functional studies. In addition, their ability to bind to HIV-1 glycoproteins was also tested by a commercial immunoblotting kit (HIV Blot 2.2; Diagnostic Biotecnology Ltd., Singapore). IgG from HIV-1+ sera unreactive to Fas (Nos. 9 and 34 from group B) were purified by DEAE-cellulose filtration to provide adequate controls to anti-Fas specificities from group A patients.

Functional Tests of Anti-Fas Antibodies. The ability of purified anti-Fas antibodies to induce apoptosis in vitro was investigated by using both CEM cells and peripheral T lymphocytes as the target in separate tests. To this purpose, 5 × 10⁶ CEM or T cells, purified by double-gradient centrifugation from patients 3, 41, and 54, were incubated for 20 h in the presence of 10 ng/ml IL-2 in 24-well plates coated with variable concentrations (0.1–10 μg/ml) of anti-Fas molecules (16). The cells were then washed and stained by the propidium iodide (PI) method to measure the extent of subdiploid DNA content as a degree of apoptosis (43). [³²P]thymidine uptake was also measured to determine the inhibition of cell proliferation after anti-Fas incubation (29). The negative controls in both experiments were IgG from anti-CM negative patients (Nos. 9 and 34), while the positive control included incubation of parallel cell preparations, with the CH11 mAb and the rFas-L at amounts similar to those adopted for anti-Fas antibodies. Control experiments investigated the possible inhibition of anti-Fas antibodies by the VEINCTR peptide and the rgp120 (Intracel, London, UK). To this purpose, anti-Fas molecules were separately preincubated with variable amounts (up to 7.5 μg/ml of VEINCTR and 1 μg/ml of rgp120) for 3 h and then used in functional tests.

Statistical Analysis. Sera with ELISA OD values higher than mean +3 SD of controls were considered positive. The distribution of subdiploid DNA content in peripheral T cells from patients showing ELISA positivities was also sought by the Wilcoxon test as a nonparametric method. In several instances, Student’s t test was also used to compare means from different samples within groups.

Results

T Cell–reactive Antibodies in HIV-1+ Patients. Fig. 1 shows the distribution of both IgG and IgM reactivities to the CEM plasma membrane. In line with our previous observations (34), we found that the majority of isolated specificities were of the IgG isotype. This pattern was predominant in seven patients, whereas four showed elevations of IgM only. In addition, a subgroup of five patients was positive for both IgG and IgM, though the OD values of IgG reac-

![Figure 1](Image 312x552)

**Figure 1.** Distribution of serum IgG and IgM reactivities by ELISA to CEM cell membrane in 74 HIV-1+ infected individuals at different CDC stages. Positive antibody titers were observed in 16 patients divided into groups A, B, and C in relation to serological elevations of IgG, IgM, or both. Numbers refer to both HIV-1+ patients and two normal donors (ND) showing weak yet definite IgM elevations to the membrane. The reactivities of the remaining 58 HIV-1+ sera are included in the shaded area whose positivity limits are the mean + 3 SD of OD values obtained from 67 uninfected controls. SD of single samples are related to outlayer values.
Activity were constantly higher within each serum. Therefore, we arbitrarily placed these patients in groups A, B, and C, depending on their serum positivities of IgG, IgM, or both. Two control subjects also displayed a moderate, though definite IgM positivity.

CEM Membrane–reactive Antibodies and Specificity to Fas. Preliminary experiments addressed the question whether the T cell–reactive antibodies detected by ELISA were able to bind Fas. Sera from the A, B, and C groups were first investigated by both immunofluorescence and immunoblotting analyses, using the human Fas-transfected WC8 lymphoblasts as the substrate. Results were related to the anti-CEM ELISA, and are expressed in Table 1 along with relative values of peripheral counts of T cells and their subdiploid DNA extent. As shown, although small numbers of comparable patients were available, serum positivities to T cell membranes were in apparent concordance with virtually all patients included in groups A and C, showing high fluorescence intensity to WC8 cell, as compared to its Fas-negative parental line (WR19L). By contrast, the reactivity of IgM to WC8 was almost undetectable, since the fluorescence intensity was less than one decade of dynamic range of the Fas-negative control. (C) Cytofluorimetric control tests of patients unreactive to CEM membrane and normal donors (ND). Representative patterns from both groups consistently showed lack of IgG and IgM reactivity to the human Fas–transfected cell line (WC8). Pt., patient.

**Figure 2.** (A) Indirect immunofluorescence assay using as substrate the human Fas transfected mouse WC8 lymphoma (top) and its Fas-negative mutant WR19L (bottom). Representative fluorescence pattern from patient 41, whose serum IgG were reactive to the WC8 membrane with no evidence of specificity to Fas-negative cells. (B) Flow cytometry analysis of Fas reactivity of T cell–reactive IgG and IgM detected by ELISA in HIV–1–infected individuals. Positive binding of IgG to the antigen occurred in virtually all patients included in groups A and C, showing high fluorescence intensity to WC8 cell, as compared to its Fas-negative parental line (WR19L). By contrast, the reactivity of IgM to WC8 was almost undetectable, since the fluorescence intensity was less than one decade of dynamic range of the Fas-negative control. (C) Cytofluorimetric control tests of patients unreactive to CEM membrane and normal donors (ND). Representative patterns from both groups consistently showed lack of IgG and IgM reactivity to the human Fas–transfected cell line (WC8). Pt., patient.

shows the fluorescence obtained by incubating serum 41 with WC8 and further treatment with FITC–anti-human IgG. This pattern was not evident when the same serum was incubated with the Fas-negative parental cell line WR19L (lower section), suggesting a relative specificity of IgG to the transfected antigen. A similar profile of positivity was also observed in other sera from group A and, to a variable extent, in sera from group C. Conversely, sera from group B constantly showed a pattern of weak fluorescence in tests using FITC–anti-IgM as the related antiserum (data not shown). Similar evidence of feeble reactivity to WC8 was also detected in IgM from the two controls (ND-11 and ND-28) with positive binding to CEM in ELISA.

Cytofluorimetric analysis for anti-Fas is presented in Fig. 2B, which shows a differential pattern of reactivity within the sera tested. While no binding to WR19L was observed in all instances, a variable reactivity to WC8 was recorded in relation to the isotype tested. IgG in sera from groups A and C were highly reactive to the Fas+ cell line, albeit in the presence of slight variations of fluorescence intensity (even more than one decade of dynamic range than WR19L) within different samples. By contrast, IgM in sera from groups B and C uniformly showed a weak to unde-
Anti-Fas Antibodies in HIV-1+ Patients

In most instances, their extent of fluorescence intensity was similar to WR19L cells. This difference supported the contention that IgG rather than IgM are highly reactive molecules to Fas. Control patterns from a number of CEM-unreactive patients and uninfected donors are shown in Fig. 2C. No evidence of positive binding to WC8 cells was demonstrated in both IgG and IgM from these control subjects, although in selected instances, such as in normal donor 28, the low fluorescence of IgM to the Fas+ membrane paralleled the moderate ELISA elevation.

Anti-Fas specificities were also determined by immunoblotting, using both WC8- and WR19L-purified membranes as substrates (Fig. 3). Once again, sera from groups A and C were reactive to a few low molecular weight bands on both lysates (upper section). IgG in most sera, however, showed a variable reactivity to a defined band that was evident only on the WC8 plasma membrane. The target antigen was apparently related to Fas, since it was re-active to the commercial mAb from clone CH11 and exhibited a similar molecular mass (~43.8 kD) in our assay. Although more specific than immunofluorescence, however, the binding to blotted Fas by IgG from group C patients was of variable intensity, in contrast with the undetectable IgM reactivity (data not shown). The lower section of Fig. 3 shows the immunoblotting pattern of CEM-unreactive patients and healthy controls. These experiments confirmed the absence of definite specificities to Fas in sera from both control groups.

Table 1. Clinical and Immunity Parameters of 16 HIV-1+ Patients

| Sera | CDC Stage | Peripheral lymphocytes | Peripheral T cells with subdiploid DNA (percentage of PI staining) | Anti-Fas IgG | Anti-Fas IgM |
|------|-----------|------------------------|----------------------------------------------------------|-------------|-------------|
|      |           | CD4+               | CD8+            |                            | FC*         | WB‡         | FC      | WB     |
| Patients |
| Group A: No. 3 | IV | 690 | 122 | 467 | 43.5 | + | + | + | + |
| 12 | III | 809 | 212 | 494 | 39.6 | + | + | + | + |
| 21 | II | 1,390 | 381 | 724 | 32.5 | + | + | ± | ± |
| 39 | IV | 1,018 | 172 | 715 | 40.8 | + | + | - | - |
| 41 | IVC | 595 | 47 | 380 | 46.5 | + | + | ± | ± |
| 54 | IV | 270 | 8 | 165 | 38.0 | + | + | - | - |
| 63 | III | 780 | 190 | 515 | 40.8 | + | + | - | - |
| Group B: No. 9 | IV | 872 | 73 | 487 | 31.5 | - | - | ± | - |
| 34 | II | 2,907 | 705 | 1,708 | 21.9 | - | - | + | - |
| 61 | IV | 965 | 153 | 565 | 27.5 | - | - | - | - |
| 78 | III | 706 | 224 | 503 | 33.0 | ± | - | - | - |
| Group C: No. 19 | III | 954 | 288 | 527 | 37.5 | + | + | - | - |
| 28 | IV | 550 | 107 | 308 | 41.5 | + | - | - | - |
| 43 | III | 1,615 | 317 | 980 | 29.5 | + | - | ± | ± |
| 59 | IVC | 675 | 28 | 426 | 43.2 | + | + | ± | ± |
| 81 | III | 1,136 | 209 | 690 | 40.5 | + | ± | - | - |
| Uninfected controls |
| ND-11 | — | 2,790 | 1,786 | 792 | 9.7 | - | - | ± | - |
| ND-28 | — | 4,170 | 2,045 | 1,215 | 11.2 | - | - | - | - |

Clinical and immunity parameters included the amplitude of the apoptotic T cell population, as measured by the content of subdiploid DNA. The peripheral lymphocytes from the 16 HIV-1+ patients showed serological reactivities to CEM membrane antigens and to human Fas-transfected mouse WC8 lymphoma cells. Data from two uninfected controls were presented in relation to their positivity detected in ELISA to CEM membrane.

*FC, flow cytometry. The positivity was related to a fluorescence intensity higher than one decade of dynamic range of the relative control.
‡WB, western blot. Positivity detection of a Fas-related band indicated as +.

Detectable affinity to the WC8 membrane, since in most instances, their extent of fluorescence intensity was similar to WR19L cells. This difference supported the contention that IgG rather than IgM are highly reactive molecules to Fas. Control patterns from a number of CEM-unreactive patients and uninfected donors are shown in Fig. 2C. No evidence of positive binding to WC8 cells was demonstrated in both IgG and IgM from these control subjects, although in selected instances, such as in normal donor 28, the low fluorescence of IgM to the Fas+ membrane paralleled the moderate ELISA elevation.

Anti-Fas specificities were also determined by immunoblotting, using both WC8- and WR19L-purified membranes as substrates (Fig. 3). Once again, sera from groups A and C were reactive to a few low molecular weight bands on both lysates (upper section). IgG in most sera, however, showed a variable reactivity to a defined band that was evident only on the WC8 plasma membrane. The target antigen was apparently related to Fas, since it was re-active to the commercial mAb from clone CH11 and exhibited a similar molecular mass (~43.8 kD) in our assay. Although more specific than immunofluorescence, however, the binding to blotted Fas by IgG from group C patients was of variable intensity, in contrast with the undetectable IgM reactivity (data not shown). The lower section of Fig. 3 shows the immunoblotting pattern of CEM-unreactive patients and healthy controls. These experiments confirmed the absence of definite specificities to Fas in sera from both control groups.

Binding to Fas was further investigated with an optimized ELISA, using the rFas-Fc as antigen. The amplitude of reactivity to Fas compared with the concurrent activity to Fc is shown in Fig. 4. A broad variation in the ability to bind the antigen was observed. High OD values were detected in group A, particularly in patients 3, 41, and 54, suggesting a remarkable correlation with the anti-CEM ELISA, whereas the total activity to rFas-Fc was apparently modest in group B and still substantial in group C. However,
ever, specificity to rFas was predominant in most sera from group A when compared to the single reactivities to Fc. Both total and IgM specificities to Fc were considerably expressed in sera from group C, suggesting that, in contrast with the potential involvement of RFs in increasing positivities to the T cell membrane, a clear-cut specificity to Fas was definitely present. Conversely, 39 patients unreactive to the CEM membrane showed no similar elevations of anti-Fas specificities in their sera, whereas, as expected, control RF-positive sera were highly reactive to Fc both in its natural and chimeric forms. In addition, the uninfected controls were constantly unreactive to the antigen (data not shown).

**Anti-Fas IgG Show Predominant Reactivity to VEINCTR–N Domain.** The next set of experiments investigated whether anti-Fas IgG in sera from groups A and C were reactive to the aa 99–108 stretch of Fas, which is also shared by the V3 loop of gp120. To this purpose, the ELISA was prepared with overlapping peptides of this domain and those resembling the V3-related homology sequence from both HIV-1iiib and HIV-1MN as the antigen. The results obtained with the most reactive sera (Nos. 3, 41, and 54) showed significant binding starting with peptide 96GLEVEINCTR 105 (Fig. 5A) and stable until 100EINCTRTQNT 109, supporting the evidence that the shared stretch alone could constitute the reactive epitope. Interestingly, construction of the peptide with N (Asn) in aa position 108 induced a small but definite increment of reactivity in IgG from serum 54. This was consistent with a potential contribution of Asn to a conformational rather than a linear domain reacting with those antibodies. Moderate and low IgM reactivities (OD 0.31) to the full-length peptide were observed in two sera from group B (Nos. 34 and 78), whereas parallel ELISA tests searching for potential specificities to the peptide in sera from patients who were unreactive to CEM membrane and from uninfected donors revealed a prevalent lack of reactivity in both control groups (data not shown).

**Fig. 5B** illustrates the pattern of IgG reactivities for the peptides that resemble the homology sequence. Predominant binding to VEINCTRPN (V3iiib) was observed in most sera from both groups. The difference between reactivities to VEINCTRPN (iiib) and VQINCTRPNY (mn) was evident in several sera (Nos. 3, 21, and 41), whereas the similar values for both peptides by IgG of serum 54 further supported the view that the presence of Asn, rather than the substitution of Glu by Gln, is essential in influencing the antigenicity of both epitopes. As expected, IgG from the controls constantly showed low values of reactivities to both peptides.

**Affinity-isolated Anti-Fas Preparations.** Serum samples from patients 3, 41, 54, and 59 containing anti-Fas were passed through Sepharose 4B columns coupled with WC8 membrane lysate and were further cleared of nonspecific antibodies by absorption on WR19L affinity columns. Fig. 6 shows the protein analysis of relative eluates detected by SDS-PAGE, using β-mercaptoethanol as the reducing agent. A prevalent IgG content was demonstrable in all samples absorbed on the lysates, even in the presence of traces of IgM, particularly in sera 41 and 59. Similarly, eluates from VEINCTR columns included IgG, although at lower concentrations than in other eluted fractions.

**Anti-Fas IgG Are Inducers of Apoptosis in Vitro.** The ability of purified anti-Fas preparations to induce cell death was investigated in vitro by different methods, including the measurement of both subdiploid DNA content and proliferative rate inhibition of target cells after their incubation with those antibodies. To this end, we used both CEM cells as a clonotypic model of CD4+ cells and, in parallel
tests, autologous T cells from the peripheral blood of the four patients providing anti-Fas. Positive controls were provided by the anti-Fas from clone CH11 and the rFas-L, whereas purified IgG from two patients of group B (9 and 34) were used as negative controls to anti-Fas. Fig. 7 shows the cytofluorimetric profiles of PI staining of treated CEM cells. As depicted in section B, anti-Fas molecules induced a remarkable increase of the subdiploid DNA peak that was particularly evident at 20 μg/ml or higher concentrations, when its extent ranged from ~63.6 to 92.5%. Both control IgG from patients unreactive to the CEM lysate failed to induce any increase in the apoptotic cell population, whereas as expected, the CH11 and the rFas-L control reagents drove >90% of cells to die (Fig. 7 A). An extension of these experiments included the evaluation of the subdiploid DNA extent in HIV-1 T cells that had been incubated with autologous anti-Fas. A similar pattern to CEM cells with occasional further increment of the apoptotic population was usually observed, whereas no evident differences were noted with heterologous as opposed to autologous anti-Fas preparations (data not shown). Fig. 7 C shows the effect of anti-Fas inhibition by the VEINCTR peptide. Preincubation of anti-Fas antibodies with increasing concentrations (0.5 to 7.5 μg/ml) of this peptide induced a major suppression of the apoptogen effect, leading to substantial recovery of the euploid DNA peak (M2). This effect paralleled the failure to react with rgp120 in control ELISA, and supported the specificity of the peptide for such anti-Fas agonist molecules.

The inhibitive effect of anti-Fas antibodies on the proliferation of CEM cells is also illustrated in Fig. 8 (left panel). Anti-Fas from serum 54 showed the highest inhibition ([3H]thymidine uptake ≤35%) at a concentration >0.1 μg/ml. The similar profile obtained with the anti-Fas from patient 41 at 1 μg/ml was significantly different (P <0.02) from the control cell preparations that were treated with purified IgG from group B patients (uptake 100% with ~19,000 cpm). Slightly less inhibition was noted with the anti-Fas from patients 3 and 59. Both preparations suppressed [3H]thymidine uptake of CEM cells by ~50%, showing that antibody concentrations >1 μg/ml were still effective in significantly suppressing their target cells (P <0.05). A strong inhibition was induced by both CH11 and rFas-L reagents in control cell suspensions, though their effect at 1 μg/ml was nearly equivalent to anti-Fas preparations from patients 41 and 54. This confirms the
susceptibility of CEM cells to activate their own Fas pathway after cross-linking with these molecules.

A control of specificity in proliferative assays was also provided using the same anti-Fas antibodies preincubated with increasing amounts of rgp120. Fig. 8 (right panel) shows that saturation of anti-Fas from the same patients with >1 μg/ml of virus glycoprotein was able to prevent the observed inhibition of proliferative rate in CEM cells that were treated with 10 μg/ml of anti-Fas. In all instances, the preincubation of these antibodies with a similar concentration of rgp120 restored the normal proliferation of those cells, suggesting the functional inactivation of anti-Fas. Conversely, control IgG unreactive to CEM were not influenced by the virus glycoprotein.

These cross-inhibiting experiments exploring the effect of anti-Fas saturation with either VEINCTR in PI measurement or rgp120 in proliferation supported the contention that our antibody preparations were specific for both Fas and gp120 to an equivalent extent.

Affinity-isolated Fas-reactive IgG Bind to gp120. The ability of anti-Fas from the four patients to bind to HIV-1 glycoproteins was tested by immunoblotting. Fig. 9 shows the reactivity to gp120 detected in WC8-absorbed anti-Fas IgG from patient 54 compared with the serum pattern of positivity to the virus lysate. Similar binding was observed in IgG from patient 54 and 59, which were purified through VEINCTR columns. A variable positivity of immunoblotting binding was also detected in the other three preparations of anti-Fas derived from WC8-coupled columns (data not shown).
Discussion

The present study demonstrates that the described increase of T cell apoptosis in HIV-1 infection could include an antibody-mediated mechanism acting via the Fas pathway. Analysis of serum reactivities in a cohort of HIV-1 patients revealed that IgG to CEM lymphoblast membrane bound Fas in both quantitative cytofluorimetry and immunoblotting, using the human Fas-transfected mouse WC8 lymphoma as a substrate, and reacted with the rFas in ELISA. Investigation of Fas epitope specificity by linear sequence peptides documented prevalence of reactivity to a domain including the 99VEINCTR–N108 peptide, also shared by the gp120 V3 loop of HIV-1 subtype B. Absorption of sera by affinity columns coupling the WC8 membrane lysate provided enriched anti-Fas IgG preparations whose effect in functional studies was nearly equivalent to either CH11 IgM anti-Fas mAb or rFas-L in induction of apoptosis in target cells. These molecules were also reactive to a peculiar epitope of gp120, however, suggesting that the humoral response elicited to that domain of the HIV-1 envelope protein may enhance T cell apoptosis by a molecular mimicry mechanism involving Fas stimulation.

A number of studies have emphasized the role of autoimmune mechanisms in the immunopathogenesis of AIDS. Disturbance of self–nonself recognition resulting from chronic activation of the immune system has been postulated to promote differential autoimmune deregulations, including GVHD condition (44), leukocyte alloimmunization (45), abnormal idiotype interactions (46), and increased cytokine secretion (47). Structural similarities between immunogenic HIV-1 envelope proteins and MHC and other key immunoregulatory molecules have recently been postulated (25, 26, 48) as the source of the chronic immune derangements, leading to the production of autoantibodies and clinical phenomena. Despite the description of peculiar syndromes that resemble idiopathic autoimmune diseases (49), however, the occurrence of autoantibodies that display pathogenic idiotypes which parallel and proceed to the late stages of disease have rarely been detected in HIV-1 patients.

Although described in <20% of HIV-1–infected indi-

---

Figure 6. SDS-PAGE pattern of isolated anti-Fas antibody preparations obtained by absorption of sera on affinity columns coupled with the Fas+ membrane lysate from WC8 cells and further absorption on WR19L lysate columns for clearance of nonspecific reactivities. A prevalent IgG content was observed in those preparations, even though traces of IgM were also present. Parallel absorptions using VEINCTR peptide–coupled affinity columns provided eluates showing a similar content of antibodies in sera 54 and 59. Standard IgM and IgG were myeloma proteins.

Figure 7. Functional studies of isolated anti-Fas molecules from patients 3, 41, 54, and 59. (A) Percentage of apoptotic CEM cells measured as the extent of PI subdiploid DNA staining (M1) induced by 20 μg/ml of agonist ligands of Fas (CH11 mAb and rFas-L) compared to the effect of control IgG from two patients unreactive to CEM membrane. (B) The extent of subdiploid DNA in cell preparations that were treated with similar concentrations of the purified anti-Fas from the four patients ranged from ~63–92%, and was apparently equivalent to the effect of functional ligands. (C) Preincubation of anti-Fas preparations with 7.5 μg/ml of VEINCTR peptide removed the ability of those antibodies to increase the PI subdiploid DNA peak, suggesting their functional saturation by the related antigen.
Anti-Fas antibodies:

- Patient #3
- " = " 41
- " = " 54
- " = " 59

Figure 8. Inhibition of CEM proliferative rate by anti-Fas preparations. Significant inhibition ($P < 0.02$) was noted in cell suspensions that were incubated with anti-Fas IgG from patients 41 and 54 by the concentration of 1 $\mu$g/ml. A moderate but significant effect ($P < 0.05$) was also recorded using anti-Fas preparations 3 and 59 at higher concentrations. The test included both positive and negative controls. The effect of both CH11 mAb and rFas-L was nearly equivalent to anti-Fas antibodies from patients, whereas the control Fas-ureactive IgG from patients 9 and 34 failed to induce significant variations of the baseline [$^3$H]thymidine uptake (left panel). Preincubation of anti-Fas with rgp120 induced in all instances a dose-dependent suppression of their inhibitory property on CEM proliferation, which was measured as the percentage of [$^3$H]thymidine incorporation. The effect of control IgG was not influenced by the recombinant glycoprotein (right panel).

Figure 9. Immunoblotting of isolated anti-Fas IgG from patient 54 on the HIV-1 lysate, as compared with serum pattern of positivities to the viral bands. The antibody was found to react with gp120 in a fashion similar to both antibody preparations (from patients 54 and 59) absorbed on VEINCTR columns. Negative control using commercial human IgG was also provided.

Individuals (31, 50, 51), autoantibodies to T cell antigens are suspected to contribute to the immunopathogenesis of AIDS, since their serum levels may parallel the progression of lymphopenia (32, 33, 51). Molecular specificities to the HIV-1 receptor (52, 53) and other membrane antigens (30, 50, 54) have been attributed to such antibodies in affecting the helper function of CD4$^+$ cells, whereas using the CD4$^+$ clonotypic CEM lymphoblasts, we documented that a receptor of $\sim 43.5$ kD was able to suppress the cytotoxic properties of those antibodies in competitive inhibition experiments (35). Evidence from this work strongly suggests that the Fas antigen is the primary molecular target of such T cell-reactive antibodies in a number of HIV-1–infected individuals.
cross-linking with the monomeric IgG1 anti-Fas mAb from clone UB-2. This reagent is a weak inducer of apoptosis in Fas+ cell lines, whereas it may costimulate the proliferation of freshly isolated T cells from uninfected donors (16). Therefore, both overexpression and susceptibility of Fas during HIV-1 infection may be crucial in the increase of peripheral T cell apoptosis.

The main question raised by this study is whether the Fas-reactive IgG detected in several patients are actually implicated in enhancing the extent of T cell apoptosis in vivo. The first answer came from indirect multiparametric analysis. Semiquantitative measurement of the cytofluorimetric PI intensity of DNA staining was enough to show that patients from groups A and C with the highest ELISA reactivities to rFas (Fig 4) showed a parallel increment of their subdiploid DNA T cell population (Table 1). Although the differences between percentages of apoptotic T cells were estimated in a comparatively small number of patients within each group, these data suggest a potential association between the occurrence of anti-Fas antibodies and an increase of apoptosis-mediated lymphopenia. This was manifest particularly in patients with advanced disease from both groups A and C. Meyaard et al. (7) have reported that the degree of T cell apoptosis may not correlate with disease progression. Accordingly, the potential linkage of uniformly accelerated cell death in patients with different CDC stages may depend on their serum elevations of IgG reactive to Fas. Despite the described association, however, our group observed extensive subdiploid DNA content in peripheral T cells from a few patients lacking serum positivities to either Fas+ cell membranes or rFas, thus supporting the assumption that, besides Fas, other mechanisms are involved in driving the increased T cell apoptosis in such patients.

A second interesting point concerned the effect of Fas-reactive IgG in functional studies. These molecules were absorbed by affinity chromatography on Fas+ membrane from WC8 cells and were demonstrated to prominently enhance the subdiploid DNA peak in cultured CEM cells, resulting in an event similar to that provoked by reagents that trigger Fas, such as the CH11 mAb and rFasL (Fig. 7, A and B). Conversely, no effect was observed in control tests using purified IgG that was unreactive to CEM membrane from two patients (Nos. 9 and 34) of group B. These findings were also sustained by the proliferative assays shown in Fig. 8. Again, the presence of anti-Fas preparations at 1 μg/ml or more, particularly from patients 41 and 54, induced a tremendous inhibition of the [3H]thymidine uptake in a fashion similar to that obtained with functional reagents.

The agonist effect of these purified anti-Fas was also cross-inhibited by either VEINCTR or rgp120, resulting in a dose-dependent lack of activity in both functional tests. Since control IgG preparations were ineffective, we concluded that such affinity-isolated anti-Fas were able to activate cytolysis of CEM cells by mimicking the natural Fas-L. Although we obtained equivalent results in experiments using autologous T cells, we reasoned that CEM lymphoblasts were an appropriate CD4+ cell target to avoid the heterogeneity of peripheral lymphocytes at different steps of maturation.

Fine mapping of Fas using a panel of 10-mer overlapping peptides revealed that the entire epitope (VEINCTR–N) shared by the V3IIIb loop of gp120 was highly reactive to the majority of sera from groups A and C (Fig. 5). With the exception of three sera (Nos. 3, 21, and 41), we found that the binding to IIIB (VEINCTRPNN) and MN (VQINCTRPNY) HIV-1 peptides was almost equivalent, and that replacement of Glu by Gln did not influence the relative antibody affinity. By contrast, the presence of Asn on both peptides slightly increased the reactivity of IgG from serum 54, suggesting that a conformational domain of gp120, including Asn, was predominantly recognized by this patient. Conformational V3 loop peptides have been reported to induce specific antibody response to HIV-1 (59). Since the majority of neutralizing antibodies to both IIIB and MN European strains of HIV-1 are prevalently directed to the gp120 V3 loop (42), however, our data suggest that within the wide humoral response to virus, only IgG elicited to that domain of the V3 loop are effective cross-linkers of Fas and are able to induce its trimerization. In this context, it has been demonstrated by Itoh et al. that the cytoplasmic signal–transducing domain of Fas, also termed death domain, is activated by receptor clustering (60). Therefore, the oligomerization of Fas by such anti-V3 IgG may account for the property of these molecules to cross-link the receptor in a self-associated molecular state.

In conclusion, our data indicate that the T cell–reactive antibodies originally described in HIV-1 infection are actually involved in aggravating the lymphopenia, although their mechanism is not complement-mediated cytolysis. Fas-mediated depletion of peripheral T cells may occur as an effect of the humoral response to HIV-1, and is apparently dependent on the fine specificity of IgG to gp120. Since these antibodies react with the described sequence of Fas, it would be of interest to determine the potential reactivity to VEINCTR–N as a screening procedure to select the patients at higher risk of severe lymphopenia, based on autologous Fas activation.

The authors are grateful to Marco Tucci, Alessandra Romito, and Antonella Frassanito for technical assistance.

This work was supported in part by the VIII AIDS Research Project (1993) from the Italian Ministry of Health, Istituto Superiore di Sanità, Rome (grant 9204.38). P. Cafforio is a recipient of an AIRC fellowship.
References

1. Laurent-Crawford, A.G., B. Krust, S. Muller, Y. Riviere, M.A. Rey-Cuillè, J.M. Bechet, L. Montagnier, and A.G. Hovanessian. 1991. The cytopathic effect of HIV is associated with apoptosis. *Virology.* 185:829–838.

2. Terai, C., R.S. Kornbluth, C.D. Pauza, D.D. Richman, and D.A. Carson. 1991. Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. *J. Clin. Invest.* 87:1710–1721.

3. Meyard, L., S.A. Otto, R.R. Jonker, M.J. Mijnster, R.P. Gougeon, and L. Montagnier. 1994. Purification and characterization of the functional soluble form of human Fas ligand. *Blood.* 83:187–196.

4. Gougeon, M.L., A.G. Laurent-Crawford, A.G. Hovanessian, and L. Montagnier. 1993. Direct and indirect mechanism mediating apoptosis during HIV infection: contribution to in vivo CD4 T cell depletion. *Semin. Immunol.* 5:187–196.

5. Groux, H., G. Torpier, D. Monte, Y. Mouton, A. Capron, and J.C. Ameisen. 1992. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus–infected asymptomatic individuals. *J. Exp. Med.* 175:331–340.

6. Wesselborg, S., O. Janssen, and D. Kabelitz. 1993. Induction of activation-induced death (apoptosis) in activated but not resting peripheral blood T cells. *J. Immunol.* 150:4338–4345.

7. Meyard, L., S.O. Otto, I.P.M. Keet, M.T. Ross, and F. Miedema. 1994. Programmed death of T cells in human immunodeficiency virus infection. No correlation with progression to disease. *J. Clin. Invest.* 93:982–988.

8. Ameisen J.C. 1992. Programmed cell death and AIDS: from hypothesis to experiment. *Immunol. Today.* 13:388–391.

9. Gougeon, M.L., S. Garcia, J. Heeney, R. Tschopp, H. Leceau, D. Guevard, V. Rame, C. Dauguet, and L. Montagnier. 1993. Programmed cell death in AIDS-related HIV and SIV infection. *AIDS Res. Hum. Retrovirus.* 9:553–564.

10. Itoh, N., S. Yonehara, A. Ishii, M. Yonehara, S. Mizushima, M. Sameshima, A. Hase, Y. Set, and S. Nagata. 1991. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. *Cell.* 67:233–243.

11. Dhein, J., P.T. Daniel, B.C. Trauth, A. Oehm, P. Möller, and P.H. Krammer. 1992. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigen. *J. Immunol.* 149:3166–3173.

12. Suda, T., and S. Nagata. 1994. Purification and characterization of the Fas-ligand that induces apoptosis. *J. Exp. Med.* 179:873–879.

13. Ju, S.T., D.J. Panka, H. Cui, R. Ettinger, M. El-Khatib, D.H. Sherr, B.Z. Stanger, and A. Marshak-Rothstein. 1995. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. *Nature (Lond.).* 373:444–448.

14. Tanaka, M., T. Suda, T. Takahashi, and S. Nagata. 1995. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. *EMBO (Eur. Mol. Biol. Organ.) J.* 14:1129–1135.

15. Yonehara, S., Y. Nishimura, S. Kishii, M. Yonehara, K. Takazawa, T. Tamatani, and A. Ishii. 1995. Involvement of apoptosis antigen Fas in clonal deletion of human thymocytes. *Int. Immunol.* 6:1849–1856.

16. Alderson, M.R., R.J. Armitage, E. Maraskovsky, T.W. Tough, E. Roux, K. Schooley, F. Ramsdell, and D.H. Lynch. 1993. Fas transduces activation signals in normal human T lymphocytes. *J. Exp. Med.* 178:2231–2235.

17. Stelder, T., S. Hahn, and P. Erb. 1994. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. *J. Immunol.* 152:1127–1133.

18. Watanabe-Fukunaga, R., C.I. Brannan, N.G. Copeland, N.A. Jenkins, and S. Nagata. 1992. Lymphoproliferative disorder in mice induced by defects in Fas antigen that mediates apoptosis. *Nature (Lond.).* 356:314–317.

19. Takashi, R., M. Tanaka, C.I. Brannan, N.A. Jenkins, N.G. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. *Cell.* 76:969–976.

20. Cohen, P.L., and R.A. Eisenberg. 1991. Single gene models of systemic autoimmunity and lymphoproliferative disease. *Annu. Rev. Immunol.* 9:243–270.

21. Mysler, E., P. Bini, J. Drappa, P. Ramos, S.M. Friedman, P.H. Krammer, and K.B. Elkon. 1994. The apoptosis-1/Fas protein in human systemic lupus erythematosus. *J. Clin. Invest.* 93:1029–1038.

22. Emlen, W., J. Niebur, and R. Kadera. 1994. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. *J. Immunol.* 152:3685–3696.

23. Nakajima, T., H. Aono, T. Hasunuma, K. Yamamoto, T. Shirai, K. Hirohata, and K. Nishioha. 1995. Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. *Arthritis Rheum.* 38:485–491.

24. Kopelman, R.G., and S. Zolla-Pazner. 1988. Association of human immunodeficiency virus infection and autoimmune phenomena. *Am. J. Med.* 84:82–86.

25. Dalgleish, A.G. 1993. For debate: what is the role of autoimmunity in AIDS? *Autoimmunity.* 15:237–244.

26. Silvestris, F., R.C. Williams, Jr., and F. Dammacco. 1995. Expression of the Fas antigen in patients infected with human immunodeficiency virus. *J. Clin. Investig.* 105:1123–1125.

27. Dalgleish, A.G. 1993. Programmed cell death in AIDS-related HIV and SIV infection. *AIDS Res. Hum. Retrovirus.* 9:553–564.

28. Silvestris, F., R.C. Williams, Jr., and F. Dammacco. 1995. Apoptosis in human immunodeficiency virus–infected asymptomatic individuals. *Virology.* 229:361–366.

29. McCloskey, T.W., N. Oyaizu, M. Kaplan, and S. Pahwa. 1995. Expression of the Fas antigen in patients infected with human immunodeficiency virus. *Cytometry.* 22:111–114.

30. Katsikis, P.D., L.A. Herzenberg, and L.A. Herzenberg. 1995. Expression of the Fas antigen in patients infected with human immunodeficiency virus. *Cytometry.* 22:111–114.

31. Dorsett, B.H., W. Cronin, and H.L. Ioachim. 1990. Presence and prognostic significance of anti-lymphocyte antibodies in human immunodeficiency virus–infected individuals. *J. Clin. Investig.* 87:1710–1721.
symptomatic and asymptomatic human immunodeficiency virus infection. *Arch. Intern. Med.* 150:1025–1028.
32. Weimer, R., V. Daniel, R. Zimmermann, K. Schimp, and G. Opelz. 1991. Autoantibodies against CD4 cells are associated with helper defects in human immunodeficiency virus-infected patients. *Blood.* 77:133–140.
33. Silvestris, F., B.S. Edwards, O.M. Sadeghi, M.A. Frassanito, R.C. Williams, Jr., and F. Dammacco. 1989. Isotype, distribution and target analysis of lymphocyte reactive antibodies in patients with human immunodeficiency virus infection. *Clin. Immunol. Immunopathol.* 53:329–340.
34. Silvestris, F., C. Azzolini, and F. Dammacco. 1992. Differential isotype expression and binding properties of T cell reactive antibodies in human immunodeficiency virus (HIV) infection. *J. Clin. Immunol.* 12:107–115.
35. Silvestris, F., P. Cafforio, A. Romito, and F. Dammacco. 1994. Molecular specificities of CD4+ T cell reactive IgG and IgM in human immunodeficiency virus (HIV-1) infection. *Clin. Immunol. Immunopathol.* 70:40–46.
36. Center for Disease Control and Prevention. 1992. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *Morb. Mortal Wkly. Rep.* 41/RR-17:1–19.
37. Itoh, N., Y. Tsujimoto, and S. Nagata. 1993. Effect of bcl-2 on Fas antigen-mediated cell death. *J. Immunol.* 151:621–627.
38. Geerligs, H.J., W.J. Weijer, W. Bloemhoff, G.W. Welling, and S. Welling-Wester. 1988. The influence of pH and ionic strength on the coating of peptides of herpes virus type 1 in an enzyme-linked immunosorbent assay. *J. Immunol. Methods* 106:239–244.
39. Silvestris, F., W. Anderson, J.S. Goodwin, and R.C. Williams, Jr. 1985. Discrepancy in the expression of autoantibodies in healthy aged individuals. *Clin. Immunol. Immunopathol.* 35:234–241.
40. Chaix, M.-L., C. Chappey, I. Couillin, W. Rozenbaum, J.-P. Levy, and S. Saragosti. 1993. Diversity of the V3 region of HIV in Paris, France. *AIDS.* 7:1199–1204.
41. Antonioli, I.M., C. Baumberger, S. Yerly, and L. Perrin. 1995. V3 sequences in primary HIV-1 infection. *AIDS.* 9:11–17.
42. Vogel, T., R. Kurth, and S. Norley. 1994. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides. *J. Immunol. 153:1895–1904.
43. Nicoletti, I., G. Migliorati, M.C. Pagliacci, F. Grignani, and C. Riccardi. 1991. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. *J. Immunol. Methods* 139:271–275.
44. Habeshaw, J., E. Hounsell, and A. Dalgleish. 1992. Does the HIV envelope induce a chronic graft-versus-host-like disease? *Immunol. Today.* 13:207–210.
45. Shearer, G.M. 1983. Allogenic leukocytes as a possible factor in induction of AIDS in homosexual men. *N. Engl. J. Med.* 308:223–224.
46. Hoffman, G.W., T.A. Kion, and M.D. Grant. 1991. An idiotype network model for AIDS pathogenesis. *Proc. Natl. Acad. Sci. USA.* 88:3060–3064.
47. Meroni, L., D. Trabattoni, C. Balotta, C. Riva, A. Gori, M. Moroni, M.L. Villa, M. Clerici, and M. Galli. 1996. Evidence for type 2 cytokine production and lymphocyte activation in the early phases of HIV-1 infection. *AIDS.* 10:23–30.
48. Lopalco, L., C. Desantis, R. Menevery, R. Longhi, E. Ginelli, F. Grassi, A.G. Siccardi, and A. Beretta. 1993. Human immunodeficiency virus type 1 gp120 C5 region mimics the HLA class I α1 peptide-binding domain. *Eur. J. Immunol.* 23:2016–2021.
49. Kaye, B.R. 1989. Rheumatologic manifestations of infection with human immunodeficiency virus (HIV). *Ann. Int. Med.* 111:158–171.
50. Warren, R.Q., E.A. Johnson, R.P. Donnelly, M.F. Lavia, and K.J. Jang. 1988. Specificity of anti-lymphocyte antibodies in sera from patients with AIDS related complex (ARC) and healthy homosexuals. *Clin. Exp. Immunol.* 73:168–173.
51. Ozturk, G.E., P.F. Kohler, C.R. Horsburgh, and C.H. Kirkpatrick. 1988. The significance of anti-lymphocyte antibodies in patients with acquired immunodeficiency syndrome and their sexual partners. *J. Clin. Immunol.* 7:130–139.
52. Kowalski, M., B. Ardan, L. Basiripour, Y. Lu, D. Blohm, W. Haseltine, and J. Sodroski. 1989. Antibodies to CD4 in individuals infected with human immunodeficiency virus type 1. *Proc. Natl. Acad. Sci. USA.* 86:3346–3350.
53. Sekigawa, I., J.E. Groopmen, J.D. Allan, K. Ikeuchi, G. Bibberfeld, K. Takatsuki, and R.A. Byrn. 1991. Characterization of autoantibodies to the CD4 molecule in human immunodeficiency virus infection. *Clin. Immunol. Immunopathol.* 58:145–153.
54. Ardan, B., M.A. Sikorski, M. Settles, and D.E. Stauton. 1990. Human immunodeficiency virus type 1-infected individuals make autoantibodies that bind to the CD43 on normal thymic lymphocytes. *J. Exp. Med.* 172:1151–1158.
55. Dhein, J., H. Walczac, C. Baumler, K.-M. Debatin, and P.H. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1(Fas/CD95). *Nature (Lond.).* 373:438–441.
56. Brunner, T., R. Mogill, D. LaFace, N.J. Yoo, A. Mahboub, F. Echeverri, S.J. Martin, W.R. Force, D.H. Lynch, C.F. Ware, and D.R. Green. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridoma. *Nature (Lond.).* 373:441–444.
57. Kägi, D., F. Vignaux, B. Lederman, K. Bürki, V. Deprettere, S. Nagata, H. Hengartner, and P. Golstein. 1994. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. *Science (Wash. DC).* 265:528–530.
58. Gehri, R., S. Hahn, M. Rothen, M. Steuerwald, R. Nuesch, and P. Erb. 1996. The Fas receptor in HIV infection: expression on peripheral blood lymphocytes and role in the depletion of T cells. *AIDS.* 10:9–16.
59. Bukawa, H., J. Fukushima, K. Hamajima, M. Kimura, T. Tsuji, K-Q. Xin, and K. Okuda. 1995. Antibody responses raised against a conformational V3 loop peptide of HIV-1. *Microbiol. Immunol.* 39:607–614.
60. Itoh, N., and S. Nagata. 1993. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. *J. Biol. Chem.* 268:10932–10937.